氨磺必利与齐拉西酮对精神分裂症的随机、开放性对照研究

目的：比较氨磺必利与齐拉西酮在治疗精神分裂症的疗效和不良反应。方法：将78例符合标准的成年精神分裂症患者随机分为两组,氨磺必利组（n=38）口服氨磺必利治疗;齐拉西酮组（n=40）口服齐拉西酮治疗。观察8周。于治疗前以及治疗后第2周、第4周、第8周末,用PANSS量表评定临床效果,用不良反应量表（TESS）评定不良反应。结果：治疗结束时,两组PANSS评分较入组时均有显著降低（P〈0.05）,两组组间比较,无明显差异（P〉0.05）,两者不良反应较少两组间比较无明显差异（P〉0.05）。结论：氨磺必利与齐拉西酮对精神分裂症的治疗安全有效,氨磺必利对情感症状较齐拉西酮有更好的治疗效果。

Randomized and open control study for amisulpride and ziprasidone in treatment of schizophrenia

Objective： To compare efficacy and adverse reactions of amisulpride and ziprasidone in treatment of schizophrenia.Methods： 78 adult cases of schizophrenia meeting the diagnostic criteria were randomly assigned to amisulpride group（n = 38）（orally taking amisulpride for 8 weeks） and ziprasidone group（n = 40）（orally taking ziprasidone for 8 weeks）.The efficacy and adverse reactions were evaluated with PANSS and TESS before and 2,4,and 8 weeks after the treatment.Results： After the treatment,the scores of PANSS in both groups decreased significantly compared with the baseline（P 0.05）.Both group had fewer adverse reactions.Conclusions： Amisulpride and ziprasidone are safe and effective in the treatment of schizophrenia,however,amisulpride is better than ziprasidone for treating depress symptoms.